The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab.

Shen Lin,Yiyuan Li,Dian Gu,Shaohong Luo,Xiaoting Huang,Liangliang Dong,Xiongwei Xu, Peili Lin,Xiuhua Weng

Frontiers in oncology（2022）

引用 0|浏览2

暂无评分

摘要

In the high PD-L1 expression population, both atezolizumab and pembrolizumab were cost-effective for stage IV NSCLC compared to chemotherapy, which is contrary to that in any PD-L1 expression population. Atezolizumab shows a higher acceptability in both populations. Treating with immune checkpoint inhibitors (ICIs) has a substantial budgetary impact on the medical burden. The PD-L1 expression level has the potential to be a predictor for the economics of ICIs.

查看译文

关键词

PD-L1 expression level,atezolizumab,budgetary impact analysis,cost-effectiveness analysis,non-small cell lung cancer,pembrolizumab,predictor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要